AbbVie Reports Positive Phase 3 Results for Multiple Myeloma Therapy

The phase 3 trial focused on patients with triple-class exposed multiple myeloma, a difficult-to-treat form of blood cancer. By demonstrating superior efficacy against existing therapies, the drug has positioned itself as a significant candidate in the company’s oncology pipeline. AbbVie now intends to engage with global regulatory bodies to map out the path toward potential approval and commercialization.

"These results underscore our confidence in etentamig and our broader multiple myeloma strategy, which explores complementary T-cell engagers, targeted small molecules and rational combinations designed to address distinct disease mechanisms and patient needs," said Daejin Abidoye, head of oncology, solid tumor and hematology at AbbVie. The company continues to prioritize its portfolio of T-cell engagers as it looks to expand its footprint in hematological treatments.